Effect of genetic variation in Notch regulator DTX1 on SCLC prognosis compared with the effect on NSCLC prongosis

DTX1 rs1732786A>G was associated with better prognosis in patients with early ‐stage non‐small cell lung cancer, in the previous study. DTX1 rs1732786A>G was associated with a significantly worse chemotherapy response and lower overall survival in small cell lung cancer. Deltex ‐1 (DTX1) is a negative regulator of the Notch signaling pathway. Here, we investigated the clinical effect ofDTX1 rs1732786A  >  G, which is associated with better prognosis in patients with early‐stage non‐small cell lung cancer (NSCLC), in 261 patients with small cell lung cancer (SCLC).DTX1 rs1732786A  >  G was associated with a significantly worse chemotherapy response and lower overall survival in the codominant model (odds ratio = 0.42, 95% confidence interval [CI]: 0.26–0.66,P = 2  × 10−4; hazard ratio = 1.47, 95% CI: 1.17 –1.84,P = 0.001, respectively). An in vitro luciferase assay was performed, and the 1732786G allele demonstrated significantly higher promoter activity than the 1732786A allele (P = 2  × 10−7). In summary,DTX1 rs1732786A  >  G was associated with poor prognosis in patients with SCLC as opposed to patients with NSCLC.Key pointsSignificant findings of the studyDTX1 rs1732786A  >  G was associated with better prognosis in patients with early‐stage non‐small cell lung cancer (NSCLC) in our previous study.What this study addsDTX1 rs1732786A  >  G was associated with a significantly worse chemotherapy response...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: BRIEF REPORT Source Type: research